New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.

An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.

A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.

How should a factor XIa inhibitor be incorporated into secondary stroke prevention?

Inconsistent state immunization laws complicate pharmacy operations and limit patient access.

Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.